Capitolis Advisors LLC Eli Lilly & CO Transaction History

Capitolis Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$234.69 - $291.66 $11.7 Million - $14.6 Million	-49,920 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$224.85 - $279.04 $2.26 Million - $2.8 Million	10,039 Added 25.17%	49,920 $13.8 Million
Q3 2021 Nov 12, 2021	BUY	$221.6 - $272.71 $1.79 Million - $2.2 Million	8,077 Added 25.4%	39,881 $9.53 Million
Q2 2021 Aug 11, 2021	SELL	$180.55 - $233.54 $6.36 Million - $8.23 Million	-35,224 Reduced 52.55%	31,804 $7.3 Million
Q1 2021 May 13, 2021	SELL	$164.32 - $212.72 $2.05 Million - $2.66 Million	-12,483 Reduced 15.7%	67,028 $12.5 Million
Q4 2020 May 07, 2021	BUY	$130.46 - $172.63 $10.4 Million - $13.7 Million	79,511 New	79,511 $13.4 Million

4,073

737M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $771B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Capitolis Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Capitolis Advisors LLC with notifications on news.